Published in Health and Medicine Week, July 11th, 2005
According to a study from the United States, "AN1792 (beta-amyloid [A-beta] 1-42) immunization reduces A-beta plaque burden and preserves cognitive function in APP transgenic mice. The authors report the results of a phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningo-encephalitis in 6% of immunized patients.
"This randomized, multicenter, placebo-controlled, double-blind trial of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week